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Abstract
With the hope of understanding how interleukin (IL)-4 and IL-13 modulated quality of anti-viral CD8+ T cells, we evaluated
the expression of receptors for these cytokines following a range of viral infections (e.g. pox viruses and influenza virus).
Results clearly indicated that unlike other IL-4/IL-13 receptor subunits, IL-4 receptor a (IL-4Ra) was significantly down-
regulated on anti-viral CD8+ T cells in a cognate antigen dependent manner. The infection of gene knockout mice and wild-
type (WT) mice with vaccinia virus (VV) or VV expressing IL-4 confirmed that IL-4, IL-13 and signal transducer and activator of
transcription 6 (STAT6) were required to increase IL-4Ra expression on CD8+ T cells, but not interferon (IFN)-c. STAT6
dependent elevation of IL-4Ra expression on CD8+ T cells was a feature of poor quality anti-viral CD8+ T cell immunity as
measured by the production of IFN-c and tumor necrosis factor a (TNF-a) in response to VV antigen stimulation in vitro. We
propose that down-regulation of IL-4Ra, but not the other IL-4/IL-13 receptor subunits, is a mechanism by which CD8+ T
cells reduce responsiveness to IL-4 and IL-13. This can improve the quality of anti-viral CD8+ T cell immunity. Our findings
have important implications in understanding anti-viral CD8+ T cell immunity and designing effective vaccines against
chronic viral infections.
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Introduction
Protection against intracellular pathogens (e.g. viruses and
parasites) and tumors often requires the activation of effector
CD8+ T cells, which usually mediate cytolysis upon recognition of
non-self peptide-major histocompatibility complex class I com-
plexes presented on the surface of malignant cells or virus-infected
cells [1–3]. However, a collection of CD8+ T cell effector
functions, not exclusively cytolysis, appears to be important in
controlling virus infections. These include the ability to mount
high avidity interactions with virus-infected targets, produce
multiple anti-viral cytokines (i.e. IFN-c and TNF-a), induce a
high clonal turnover rate, and/or the ability to produce
chemoattractants (e.g. macrophage inflammatory protein-1b) to
recruit immune cells to virus-infected sites [4–6]. These effector
functions define the quality of effector CD8+ T cell responses
against viruses.
IL-4 and IL-13 are closely related cytokines mostly studied for
their involvement in allergic diseases (e.g. asthma) and parasitic
infections. In our previous studies we have for the first time
demonstrated that both IL-4 and IL-13 dampen the avidity of
human immunodeficiency virus (HIV)-specific CD8+ T cells in a
pox-viral prime-boost vaccination model in mice [7–8]. Other
studies also have shown that exposure of CD8+ T cells to IL-4
during primary activation results in the differentiation of effector
CD8+ T cells with excessively reduced CD8 co-receptor expres-
sion, poor cytotoxic capacity, poor IFN-c production and
enhanced IL-4 production in vitro and in vivo [9–11].
IL-4 and IL-13 share many biological functions due to their
ability to signal through a unique network of complex receptors.
IL-4 can signal through the type I IL-4 receptor (heterodimer of
IL-4Ra and common c (cc) chains) and the type II IL-4 receptor
(heterodimer of IL-4Ra and IL-13 receptor a 1 (IL-13Ra1)
chains), but IL-13 only signals through the type II IL-4 receptor
[12,13]. IL-4 and IL-13 cytokine responses can be completely
abrogated on cells lacking IL-4Ra expression as it is a component
of both type I and type II IL-4 receptors [14–15]. IL-13 binds with
higher affinity to IL-13 receptor a 2 (IL-13Ra2) compared to IL-
13Ra1, but binding of IL-13 to IL-13Ra2 does not result in
signaling [16]. IL-13Ra2 has been shown to be important in
dampening IL-13 signaling and protecting mice against allergen
induce dermatitis [17]. Hence, IL-13Ra2 is thought to function as
an IL-13 decoy/inhibitor receptor. IL-4 and IL-13 cellular
signaling via the type I or type II IL-4 receptors leads to activation
of STAT6, which facilitates transcription of IL-4/IL-13 responsive
genes [18–19].
The use of IL-4Ra 2/2, IL-13Ra1 2/2, cc 2/2 and IL-13Ra2
2/2 mice have shown that these receptors are indeed important
for controlling functions of IL-4 and IL-13 in allergic diseases and
parasitic infections [15,17,20]. However, these studies provide
limited insight as to how these receptors are regulated at a cellular
level in vivo during the course of a pathogenic infection. Recent
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study by Tanaka et al [21] reported that cell surface IL-4Ra
expression is down-regulated on activated CD4+ T cells in vivo
following L. major infection. This was found to be due to
degradation of IL-4Ra in intracellular compartments of activated
CD4+ T cells in a T cell receptor and dedicator of cytokinesis 2
dependent manner [21]. In another study, Perona-Wright et al
[22] have also shown that cell surface IL-4Ra expression was
down-regulated on activated CD4+ T cells following H. polygyrus
infection of mice, which was thought to render these cells
refractory to further stimulation with IL-4. On the contrary, naı¨ve
bystander CD4+ T cells in this instance were found to up-regulate
IL-4Ra making them more responsive to IL-4 [22]. These studies
suggest that IL-4Ra play a critical role in tuning responsiveness of
CD4+ T cells to IL-4 and/or IL-13 during infection with
pathogens.
Despite recent studies showing the importance of regulating IL-
4Ra expression on CD4+ T cells following parasitic infection in
vivo, only few studies have addressed how the cytokine receptors for
IL-4/IL-13 are regulated on CD8+ T cells following virus infection
in vivo. As our previous studies have shown that IL-4 and IL-13
play an important role in modulating the quality of anti-viral
CD8+ T cell immunity [7–8], in this study we further investigated
how IL-4Ra, cc, IL-13Ra1 and IL-13Ra2 were regulated on
CD8+ T cells and other immune cells predominantly following VV
infection of mice. Results indicated that IL-4Ra expression, but
not cc, IL-13Ra1 or IL-13Ra2 was differentially regulated on
CD8+ T cells as a consequence of VV infection of mice. Therefore,
the current study focused on the mechanisms involved in the
regulation of IL-4Ra on CD8+ T cells following virus infection and
whether differential regulation of IL-4Ra on CD8+ T cells affects
the quality of anti-viral CD8+ T cell immunity.
Results
Regulation of IL-4/IL-13 receptor components during VV
infection
To examine whether VV infection induced differential regula-
tion of IL-4/IL-13 receptor subunits on immune cells known to be
important for clearance of viral infections, splenocytes from
unimmunized or VV Western Reserve (VV-WR) strain infected
BALB/c WT mice were analyzed using flow cytometry during the
peak (i.e. 7 days) of anti-viral immunity. Cell surface IL-13Ra1, cc
and intracellular IL-13Ra2 expression levels on gated B220+,
CD4+, CD8+, DX5+ (natural killer cells) and CD11chigh I-A
d
high
(dendritic cells (DCs)) splenocytes from VV-WR infected mice and
unimmunized mice were similar (figure 1). Cell surface IL-13Ra2
expression was not detectable above background expression levels
in the cell subsets shown in figure 1 (data not shown). Interestingly,
cell surface IL-4Ra expression was up-regulated on CD11chigh I-
Adhigh cells and down-regulated on CD4
+ T cells and CD8+ T cells
as a consequence of VV infection (figure 1). Down-regulation of
IL-4Ra was not uniformly observed on all CD4+ or CD8+ T cells
following VV infection with some cells retaining similar IL-4Ra
expression levels to that observed in unimmunized mice.
Down-regulation of IL-4Ra expression correlates with the
magnitude of effector CD8+ T cells
To clearly understand the mechanisms responsible for mediat-
ing down-regulation of cell surface IL-4Ra expression on CD8+ T
cells following VV infection, the kinetics of down-regulation of cell
surface IL-4Ra expression on CD8+ T cells from the spleens of
BALB/c WT mice infected with VV-WR was monitored. Using
intracellular cytokine staining (ICS) and granzyme B (GzmB)
expression assays, data revealed that VV-specific effector CD8+ T
cells emerged on day 5 post-infection (p.i.), peaked on day 7 p.i.
and gradually declined from days 14–28 p.i. with VV-WR
(figure 2A and 2B). Similarly, reduction in cell surface IL-4Ra
expression on CD8+ T cells following VV-WR infection was
detected on day 5 p.i., peaked on day 7 p.i. and declined from days
14–28 p.i. (figure 2C). Thus, the magnitude of down-regulation of
IL-4Ra expression on CD8+ T cells correlated with the increase in
the magnitude of the anti-viral effector CD8+ T responses
following VV infection.
Down-regulation of IL-4Ra is restricted to virus-specific
CD8+ T cells
Next the OT-I T cell receptor transgenic system was used to
show whether IL-4Ra down-regulation was restricted to CD8+ T
cells responding to virus. Splenocytes from OT-I mice (CD45.2+)
were transferred intravenously (i.v.) into congenic C57BL/6.SJL
(CD45.1+; CD45.22) recipient mice prior to infection of these
mice with VV-WR expressing the ovalbumin peptide SIINFEKL
(VV-OVA257–264) or VV-WR, which does not express OVA257–264
(SIINFEKL) epitope. CD8+ T cells from OT-I mice almost
exclusively recognize KbOVA257–264 and so should only be primed
by VV-OVA257–264 and not VV-WR. This was confirmed using
GzmB as a marker of activation (figure 3A). IL-4Ra levels were
also measured (figure 3B and 3C), and down-regulation of this
receptor on OT-I cells (CD45.2+) was only seen in mice infected
with VV-OVA257–264. By contrast IL-4Ra levels were reduced on
recipient (CD45.22) CD8+ T cells irrespective of the strain of
virus. Thus, IL-4Ra levels were only reduced on activated virus-
specific CD8+ T cells.
Down-regulation of IL-4Ra is a general property of
activated anti-viral CD8+ T cells
To evaluate whether down-regulation of cell surface IL-4Ra
expression on activated CD8+ T cells is specific to VV infections,
we analyzed IL-4Ra expression on effector (GzmB+ CD62L2) and
naı¨ve (GzmB2 CD62L+) CD8+ T cells as described in Yuen et al
[23] following infection of BALB/c WT mice with VV-WR,
modified vaccinia Ankara (MVA), avirulent Semliki Forest virus
(aSFV), fowlpox virus (FPV) or A/PR8 (H1N1) influenza virus
(figure 4A). Cell surface IL-4Ra expression on effector (GzmB+
CD62L2) CD8+ T cells compared to naı¨ve bystander (GzmB2
CD62L+) CD8+ T cells was significantly lower in all the mice
infected with the different viruses (figure 4B and 4C). There were
no significant differences between the levels of cell surface IL-4Ra
expression on effector CD8+ T cells or naı¨ve CD8+ T cells that
developed following VV-WR infection and other viral infections
(figure 4B and 4C). Therefore, down-regulation of cell surface IL-
4Ra expression on activated CD8+ T cells is a general feature of
virus infections in vivo.
Importance of IL-4, IL-13, IFN-c and STAT6 in regulating
IL-4Ra expression on CD8+ T cells following virus
infection
IL-4, IL-13 and IFN-c are cytokines that play a role in
regulating IL-4Ra expression on cells [12,24]. Thus, we next
determined whether down-regulation of cell surface IL-4Ra
expression on anti-viral effector CD8+ T cells was dependent on
IL-4, IL-13, STAT6 or IFN-c. For this purpose, IL-4Ra
expression was analyzed on effector (GzmB+ CD62L2) and naı¨ve
(GzmB2 CD62L+) CD8+ T cells from relevant gene knockout
mice and littermate WT control mice infected with VV-WR. Cell
surface IL-4Ra expression on naı¨ve CD8+ T cells, but not effector
CD8+ T cells was significantly lower in BALB/c IL-4 2/2, BALB/
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c IL-13 2/2 and BALB/c STAT6 2/2 mice compared to BALB/c
WT control mice (figure 5A and 5B). We also examined whether a
similar trend applied to CD4+ T cells in these experiments.
However, when comparing cell surface IL-4Ra expression on
naı¨ve (CD62Lhi CD44lo) or effector (CD62Llo CD44hi) CD4+ T
cells from WT mice and gene knockout mice, no differences were
observed (data not shown).
In these experiments, we also compared IL-4Ra expression
levels on naı¨ve CD8+ T cells from VV-WR infected mice and
unimmunized mice. This was done to investigate the possibility
that VV-WR infection induced IL-4 and/or IL-13 to up-regulate
IL-4Ra expression on naı¨ve bystander CD8+ T cells similar to
what has been reported on naı¨ve bystander CD4+ T cells
responding to IL-4 following parasitic infection [22]. However,
naı¨ve CD8+ T cells from VV-WR infected BALB/c IL-13 2/2,
BALB/c IL-4 2/2, BALB/c STAT6 2/2, or BALB/c WT mice
expressed similar levels of cell surface IL-4Ra to that of naı¨ve
CD8+ T cells from unimmunized mice belonging to the respective
genetic background (figure 5C). This suggests that VV-WR
infection was not inducing significant levels of IL-4 and/or IL-
13 to up-regulate IL-4Ra expression on naı¨ve CD8+ T cells. In
contrast to the knockout mice described above, no difference in
IL-4Ra expression levels were seen on any CD8+ T cells from
C57BL/6 IFN-c 2/2 compared to C57BL/6 WT controls
(figure 5A and 5B). Collectively, data suggest that IL-4, IL-13
and STAT6 are required for maintaining high levels of IL-4Ra
expression on naı¨ve CD8+ T cells.
Increased IL-4 during virus infection induces higher levels
of IL-4Ra on CD8+ T cells
Next we investigated whether IL-4Ra levels on CD8+ T cells
were fixed/unchanged, or responsive to IL-4 during infection. For
these studies VV co-expressing murine IL-4 and hemagglutinin
(HA), namely VV-HA-IL-4 [25], and the control VV co-
expressing HA (VV-HA) were used. Strikingly, IL-4Ra expression
was higher in BALB/c WT mice infected with VV-HA-IL-4
relative to VV-HA infection when comparing naı¨ve (GzmB2
CD62L+) or effector (GzmB+ CD62L2) CD8+ T cells (figure 6).
However, when the same experiment was performed using BALB/
c STAT6 2/2 mice, no difference in IL-4Ra expression was
observed (figure 6). Data indicate that the amount of IL-4 available
Figure 1. Distribution of IL-4Ra, cc, IL-13Ra1 and IL-13Ra2 on immune cells following VV infection. BALB/c WT mice (n = 12) infected for
7 days with VV-WR or unimmunized were sacrificed and splenocytes harvested for analysis using flow cytometry. The histogram plots show cell
surface expression of IL-4Ra, cc, IL-13Ra1 and intracellular expression of IL-13Ra2 on gated B220+, CD4+, CD8+, DX5+, and CD11chigh I-A
d
high
splenocytes from a representative VV-WR infected mouse (black lines) and an unimmunized mouse (grey lines). The plots are representative of at
least 12 mice tested in at least three independent experiments.
doi:10.1371/journal.pone.0055788.g001
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during virus infection can regulate the expression of IL-4Ra on
CD8+ T cells in a STAT6 dependent manner.
IL-4 and IL-13 regulate the establishment of IFN-c+ TNF-
a+ producing effector CD8+ T cells following virus
infection
High avidity virus-specific CD8+ T cells express elevated levels
of both IFN-c and TNF-a [8,26]. To evaluate whether differential
regulation of cell surface IL-4Ra expression on CD8+ T cells may
play a role in regulating CD8+ T cell functional quality, IFN-c and
TNF-a production were measured using ICS following in vitro
A5275–83 or F226–34 peptide stimulation of splenocytes from VV
infected BALB/c WT mice and gene knockout mice. Amongst the
gene knockout mice examined only BALB/c IL-4 2/2 mice
developed greater numbers of IFN-c expressing KdA5275–83 or
KdF226–34 specific-CD8
+ T cells compared to BALB/c WT
control mice following VV-WR infection (figure 7B). However, the
enhancement in cell numbers in this instance was not robust
enough to reach statistical significance (figure 7B). The number of
IFN-c+ TNF-a+ KdA5275–83 or K
dF2L26–34 specific-CD8
+ T cells
and the proportion of KdA5275–83 or K
dF2L26–34 specific-CD8
+ T
cells that expressed TNF-a in addition to IFN-c was higher in VV-
WR infected BALB/c IL-13 2/2, BALB/c IL-4 2/2 and BALB/c
IL-STAT6 2/2 mice compared to BALB/c WT control mice
(figure 7). Given that IL-4Ra expression on naı¨ve CD8+ T cells
was lower in BALB/c IL-13 2/2, BALB/c IL-4 2/2 and BALB/c
IL-STAT6 2/2 mice compared to BALB/c WT mice (figure 5), in
these studies, lower IL-4Ra expression on naı¨ve CD8+ T cells
correlated with the enhancement in the anti-viral IFN-c+ TNF-a+
CD8+ T cell responses.
Consistent with the above findings, infection of BALB/c WT
mice with VV-HA-IL-4 compared to VV-HA control infection
significantly reduced the numbers of IFN-c+ and IFN-c+ TNF-a+
KdA5275–83 or K
dF226–34 specific-CD8
+ T cells (figure 8A and
8C). The proportion of KdA5275–83 or K
dF226–34 specific-CD8
+ T
cells that expressed TNF-a in addition to IFN-c was also
significantly reduced in BALB/c WT mice infected with VV-
HA-IL-4 compared to VV-HA (figure 8A and 8C). Unlike that
observed with BALB/c WT mice, infection of BALB/c STAT6 2/2
mice with VV-HA-IL-4 compared to VV-HA control did not
Figure 2. Reduction in IL-4Ra expression correlates with magnitude of anti-viral effector responses on CD8+ T cells. Unimmunized or
VV-WR infected BALB/c WT mice (n = 4 per group) were sacrificed at the indicated time points and splenocytes used for flow cytometry analysis or for
ICS following A5275–83 or F226–34 in vitro peptide stimulation of splenocytes as described in the materials and methods. A and B, The mean (n = 4)
percentage of CD8+ splenocytes (A) and the total number of CD8+ splenocytes (B) from VV-WR infected mice that expressed GzmB or IFN-c following
in vitro peptide stimulation. C, The kinetics of the mean (n = 4) net fold reduction in cell surface expression of IL-4Ra on gated CD8+ splenocytes from
VV-WR infected mice relative to unimmunized mice. Net fold reduction was calculated using MFI values as described in the materials and methods.
The data shown are representative of at least two independent experiments and the error bars depict the SEM.
doi:10.1371/journal.pone.0055788.g002
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impair the IFN-c and TNF-a cytokine production capacity of
KdA5275–83 or K
dF226–34 specific-CD8
+ T cells (figure 8B and
8C). Thus, elevation of IL-4Ra expression on CD8+ T cells
during virus infection strongly correlated with the reduction of
anti-viral IFN-c+ TNF-a+ CD8+ T cell responses.
Discussion
Our results clearly indicated that amongst the different IL-4/IL-
13 receptor components only cell surface IL-4Ra expression was
significantly down-regulated on activated CD8+ T cells following
virus infection. IL-4, IL-13 and STAT6 were required to elevate
IL-4Ra expression on naı¨ve CD8+ T cells, but not IFN-c. VV-
HA-IL-4 infection studies showed that IL-4 and STAT6 was
required to up-regulate IL-4Ra expression on naı¨ve and effector
CD8+ T cells. In all these studies higher IL-4Ra expression on
CD8+ T cells strongly correlated with the reduction in polyfunc-
tional or IFN-c+ TNF-a+ anti-viral CD8+ T cells. Thus, we
propose that regulation of IL-4Ra expression during virus
infection plays an important role in regulating the quality of
anti-viral CD8+ T cell immunity.
Contrary to other studies [12], our data showed that IL-13Ra1
is ubiquitously expressed on CD4+ T cells, CD8+ T cells, B cells,
natural killer cells and DCs. Similar ubiquitous expression on
immune cells was also observed with respect to IL-4Ra, cc, and
IL-13Ra2. However, following virus infection only IL-4Ra was
notably differentially regulated on certain immune cell subsets (i.e.
CD4+ T cells, CD8+ T cells and DCs). The mechanisms
responsible for regulating IL-4Ra expression on CD4+ T cells
and DCs following virus infection were not investigated in this
study and warrants further investigation especially given the
importance of these cell subsets in driving immune responses that
help control intracellular pathogens [4,27].
In an acute lymphocytic choriomeningitis virus (LCMV)
adoptive transfer model, Wherry et al [28] have reported changes
in many cellular markers, including IL-4Ra expression on
Figure 3. Cell surface down-regulation of IL-4Ra specifically occurs on activated CD8+ T cells. Naı¨ve C57BL/6.SJL (CD45.1+; CD45.22) mice
(n = 6 group) that received 106106 C57BL/6 OT-I splenocytes (CD45.2+) i.v. were kept unimmunized or infected i.p. with 56106 PFU of VV-WR or VV-
OVA257–264 for 7 days prior to sacrifice and flow cytometry analysis. A, Representative contour plots showing cell surface CD45.2 and intracellular
GzmB expression on gated CD8+ splenocytes from a recipient mouse of the indicated group. B, Representative histogram plots showing cell surface
IL-4Ra expression on gated CD8+ CD45.22 (left column of plots) or CD8+ CD45.2+ (right column of plots) splenocytes from a recipient mouse kept
unimmunized, infected with VV-WR or VV-OVA257–264. C, Mean (n = 6) MFI representing cell surface IL-4Ra expression on gated CD8
+ CD45.22 or CD8+
CD45.2+ splenocytes from recipient mice of the indicated group. One-way ANOVA (Tukey’s Multiple Comparison) was used for testing significance of
the data (*** - p,0.001). Similar results have been obtained in three independent experiments and the error bars depict the SEM.
doi:10.1371/journal.pone.0055788.g003
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transferred LCMV DbGP33-specific transgenic P14 CD8+ T cells.
In their model, IL-4Ra expression was down-regulated on LCMV
DbGP33-specific CD8+ T cells following acute and chronic
LCMV infection. These findings are consistent with the findings
of the current study. However, unlike the current study, Wherry et
al [28] did not investigate the factors responsible for regulating IL-
4Ra expression on polyclonal CD8+ T cells or the implications of
regulating this receptor on CD8+ T cell functionality following
virus infection in WT mice.
IL-4 can induce the activation of STAT1, STAT3, STAT5 and
STAT6 on naı¨ve and activated CD8+ T cells in vitro [29], but our
infections studies with VV-HA-IL-4 indicated that STAT6 was
indispensible for IL-4 mediated up-regulation of cell surface IL-
4Ra expression on naı¨ve and effector CD8+ T cells. Even in naı¨ve
gene knockout mice STAT6 signaling, which appeared to be
optimal in the presence of both IL-4 and IL-13, was required to
maintain high levels of cell surface IL-4Ra expression on CD8+ T
cells. Thus, our data indicated that IL-4 and/or IL-13 signaling
through STAT6 was important in maintaining high levels of IL-
4Ra expression on naı¨ve CD8+ T cells even when no pathogen is
encountered. Furthermore, this signaling mechanism also appears
to be important in elevating IL-4Ra expression on naı¨ve and
effector CD8+ T cells in vivo following virus infection. However, a
caveat in this interpretation is that deficiency of STAT6 in other
cells may play a role in regulating IL-4Ra expression levels on
CD8+ T cells.
Previous infection studies with VV-HA-IL-4 or recombinant
ectromelia virus encoding IL-4 suggested that IL-4 dampened the
effector function capacity of anti-viral CD8+ T cells and enhanced
viral pathogenesis [25,30]. In chronic HIV progressors, HIV-
specific CD8+ T cells with reduced cytolytic capacity have been
reported to express IL-4 [31]. In our laboratory, following HIV-1
pox-viral prime-boost vaccination, both IL-4 and IL-13 were
found to dampen the avidity of HIV-specific CD8+ T cells [7].
However, none of the above studies have monitored the
expression of IL-4Ra in conjunction with the anti-viral effector
functions on CD8+ T cells. We have addressed this in the current
study and our data suggest that enhancing CD8+ T cell
responsiveness to IL-4 and/or IL-13 via STAT6 dependent up-
regulation of IL-4Ra expression can exacerbate the quality (IFN-c
Figure 4. Down-regulation of IL-4Ra is a general feature of activated CD8+ T cells following virus infection. BALB/c WT mice (n = 5) were
infected i.p. with 36106 PFU of the indicated viruses or kept unimmunized for 7 days prior to sacrifice and flow cytometry analysis. A, Dot plots
showing cell surface CD62L expression and intracellular GzmB expression on gated CD8+ splenocytes from a representative mouse of the indicated
group. B, Representative histogram plots showing cell surface IL-4Ra expression on the indicated CD8+ splenocyte subset from a representative
mouse infected with the indicated virus. C, Mean (n = 5) MFI representing cell surface IL-4Ra expression on the indicated splenocyte subset from mice
infected with the indicated viruses. Similar results have been obtained in three independent experiments and the error bars shown depict the SEM.
doi:10.1371/journal.pone.0055788.g004
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and TNF-a cytokine production) of anti-viral CD8+ T cell
immunity.
Paradoxical to these studies, we have also shown that HIV-
specific CD8+ T cells that developed in IL-4Ra 2/2 mice
following HIV-1 prime-boost vaccination expressed high levels of
IL-4 and IL-13, but low levels of IFN-c [7]. Other studies using
IL-4Ra 2/2 mice have also shown that IL-4Ra is required for the
maintenance of optimal CD8+ T cell cytotoxicity, IFN-c
production and memory responses [32–33]. It is highly likely that
in IL-4Ra 2/2 mice, other compensatory mechanisms may play a
role in dampening CD8+ T cell functionality as Mohrs et al [34]
have shown that T helper 2 differentiation can still occur in IL-
4Ra 2/2 mice in vivo. Identification of these compensatory
mechanisms may not only help understand mechanisms important
for regulating T cell quality, but also help reconcile the
paradoxical findings discussed above.
The exact mechanisms as to how IL-4 and/or IL-13 mediated
elevation of IL-4Ra expression on CD8+ T cells act to dampen
IFN-c and TNF-a cytokine production by anti-viral CD8+ T cells
was not addressed in this study. It is possible that activation of
suppressor of cytokine signaling (SOCS)-1 and -3 on anti-viral
CD8+ T cells is important for this effect as IL-4 and IL-13
mediated activation of these transcription factors have been shown
to dampen IFN-c and TNF-a cytokine production by keratino-
cytes [35]. IL-4 has also been shown to down-regulate the CD8 co-
receptor expression levels on antigen-specific CD8+ T cells, which
dampens the functionality of these cells [9–11]. Therefore, IL-4
and/or IL-13 mediated regulation of the CD8 co-receptor
expression levels on anti-viral CD8+ T cells may also play a role
in regulating anti-viral cytokine production and this is currently
being evaluated in an HIV-1 pox viral prime-boost vaccination
model (Wijesundara et al manuscript in preparation).
To our understanding, this is the first study to evaluate how the
different cellular receptor components for IL-4 and IL-13 are
regulated on CD8+ T cells following virus infection. Our data
suggested that differential regulation of IL-4Ra, unlike other IL-4/
IL-13 receptor components (i.e. cc, IL-13Ra1 and IL-13Ra2) play
a more critical role in determining the responsiveness of CD8+ T
Figure 5. IL-4, IL-13 and STAT6 regulate IL-4Ra expression on CD8+ T cells following VV-WR infection. Gene knockout mice (n = 5) and
respective littermate WT control mice (n = 5) were infected with VV-WR for 7 days or kept unimmunized prior to sacrifice and analysis using flow
cytometry. A, Representative histogram plots showing cell surface IL-4Ra expression on the indicated CD8+ splenocyte subset from a gene knockout
mouse or a littermate WT control mouse. B, Mean (n = 5) MFI representing cell surface IL-4Ra expression on the indicated CD8+ splenocyte subset
from mice of the indicated genetic background infected with VV-WR. C, Representative histogram plots showing cell surface IL-4Ra expression on the
indicated CD8+ splenocyte subset from an unimmunized mouse or VV-WR infected mouse belonging to the indicated genetic background. All the
results shown are representative of at least two independent experiments. Error bars when shown depict the SEM and one-way ANOVA (Tukey’s
Multiple Comparison) was used to determine the statistical significance of the data relative to WT control mice (*** - p,0.001).
doi:10.1371/journal.pone.0055788.g005
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cells to IL-4 and/or IL-13 in order to regulate the quality of anti-
viral CD8+ T cell immunity. This is consistent with our previous
studies where IL-4 and IL-13 were shown to play an important
role in modulating the avidity of HIV-specific CD8+ T cell
responses following prime-boost vaccination [7,8]. Thus, we
believe that the current findings could be exploited to design
more effective pox viral-vectored vaccines against chronic
infections such as HIV-1 where robust CD8+ T cell immunity is
required for protection. Furthermore, given that IL-4Ra is
constitutively expressed on T cells, it may easily be used as a
novel biomarker to assess T cell quality following vaccination.
Materials and Methods
Mice
Pathogen-free 6–8 weeks old female BALB/c WT, BALB/c IL-
4 2/2, BALB/c IL-13 2/2, BALB/c STAT6 2/2, C57BL/6,
C57BL/6.SJL (CD45.1) and T cell receptor transgenic C57BL/6
OT-I (CD45.2) mice were all purchased from the Australian
Phenomics Facility, the Australian National University. Associate
Professor Guna Karupiah kindly provided the C57BL/6 IFN-c 2/
2 mice used in this study.
Ethics statement
All animals were maintained and experiments were performed
in accordance with the Australian NHMRC guidelines within the
Australian Code of Practice for the Care and Use of Animals for
Scientific Purposes and in accordance with guidelines approved by
the Australian National University Animal Experimentation and
Ethics Committee (AEEC), protocol numbers JIG 74.09 and
A2011/018. All animals were monitored daily, infected mice were
scored for signs of illness and weight loss. Animals were ethically
sacrificed using cervical dislocation in accordance with the above
AEEC approved protocols.
Peptide synthesis
VV immunodominant A5275–83 (KYGRLFNEI) and F2L26–34
(SPYAAGYDL) peptides were synthesized by the Biomolecular
Resource Facility, the John Curtin School of Medical Research.
Virus and infection
VV-WR strain and recombinant VV-OVA257–264 were grown
and titrated in 143B cells. Recombinant VV-HA-IL-4 and the
control VV-HA were prepared as described in Sharma et al [25].
Figure 6. IL-4Ra is up-regulated on CD8+ T cells in a STAT6 dependent manner following VV-HA-IL-4 infection. BALB/c WT mice (n = 5)
or BALB/c STAT6 2/2 mice (n = 5) were infected with 56106 PFU of VV-HA control, VV-HA-IL-4 or kept unimmunized for 7 days prior to sacrifice and
analysis using flow cytometry. A and B, Representative histogram plots showing cell surface IL-4Ra expression (A) and the mean (n = 5) MFI of cell
surface IL-4Ra expression (B) on the indicated CD8+ splenocyte subset from infected mice of the indicated genetic background. The data shown is
representative of two independent experiments and the error bars depict the SEM. One-way ANOVA (Tukey’s Multiple Comparison) was used to
determine the statistical significance of the data relative to respective cell subset from VV-HA infected mice (*** - p,0.001).
doi:10.1371/journal.pone.0055788.g006
Involvement of IL-4Ra in CD8+ T Cell Quality
PLOS ONE | www.plosone.org 8 January 2013 | Volume 8 | Issue 1 | e55788
These stocks were kindly provided by Professor Alistair Ramsay.
FPV were grown and titrated in chick embryonic epithelial cells.
Dr. David Boyle kindly provided the FPV parent stocks. MVA,
aSFV and A/PR8 (H1N1) influenza virus stocks used in this study
were gifts from Associate Professor Guna Karupiah, Dr.
Mohammed Alsharifi and Dr. Yoichi Furuya, respectively.
All virus infections in age- and sex-matched mice were
conducted intraperitoneally (i.p.) at a dose of 36106 plaque
forming units (PFU)/mouse or 56106 PFU/mouse for a period of
7 days unless otherwise stated.
Adoptive cell transfer
Red blood cells (RBC)-depleted splenocytes from 8 weeks old
C57BL/6 OT-I mice were injected i.v. (106106 cells in 200 ml of
phosphate buffer saline) into a lateral tail vein of 8 weeks old
recipient C57BL/6.SJL mice. Subsequently, the recipient mice
were rested overnight and infected i.p. with 56106 PFU/mouse of
VV-WR control or VV-OVA257–264.
Flow cytometry
The following monoclonal antibodies against mouse antigens
and the respective isotype controls for CD8a, CD4, CD45R
(B220), CD124 (IL-4Ra), CD132 (cc), CD49b (DX5), CD62L,
CD11c and TNF-a were all obtained from Becton Dickinson (BD)
Biosciences, USA. Monoclonal antibodies against mouse GzmB,
CD45.2 and I-Ad were obtained from BioLegend, USA and
monoclonal antibodies against mouse CD213a (IL-13Ra1) and
IFN-c were obtained from eBioscience, USA. These antibodies
were used as purified, fluorescein isothiocyanate, phycoerythrin,
peridinin chlorophyll protein, pacific blue, or allophycocyanin
conjugates. Secondary fluorescein isothiocyanate conjugated anti-
goat IgG (Jackson Immuno Research, USA) was used to detect
Figure 7. IL-4 and IL-13 dampen polyfunctional (IFN-c+ TNF-a+) CD8+ T cell numbers following VV-WR infection. BALB/c IL-13 2/2,
BALB/c IL-4 2/2, BALB/c STAT6 2/2 and BALB/c WT control mice (n = 6 per group) were infected with 36106 PFU of VV-WR or kept as unimmunized
controls for 7 days prior to sacrifice and analysis using ICS after in vitro peptide stimulation. A, Representative dot plots showing IFN-c and TNF-a
expression on gated CD8+ splenocytes from VV-WR infected mice of the indicated genetic background following in vitro stimulation of splenocytes
with the indicated peptides. B, Mean (n = 6) total number of KdA5275–83 or K
dF226–34 specific CD8
+ IFN-c+ or CD8+ IFN-c+ TNF-a+ splenocytes from the
indicated mice infected with VV-WR. C, Mean (n = 6) proportion of KdA5275–83 or K
dF226–34 specific CD8
+ IFN-c+ splenocytes that also produced TNF-a
from the indicated mice infected with VV-WR. The data presented in all panels are representative of at least two independent. Error bars depict the
SEM and statistical significance was determined using a one-way ANOVA (Tukey’s Multiple Comparison) relative to WT control mice (* - p,0.05; *** -
p,0.001).
doi:10.1371/journal.pone.0055788.g007
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purified polyclonal goat IgG anti-mouse IL-13Ra2 (R&D systems,
USA) binding to splenocytes.
In all flow cytometry-based studies RBC-depleted splenocytes
were used. Cell surface staining and intracellular staining were
performed using the respective method described in Ranasinghe et
al [36]. Briefly, for cell surface staining 1–26106 cells were
incubated 30 minutes at 4uC in the presence of purified or
fluorochrome conjugated antibodies diluted in phosphate buffer
saline containing 1% fetal calf serum (FCS). Subsequently, samples
were washed twice using phosphate buffer saline containing 1%
FCS, fixed in 0.5% paraformaldehyde, prior to analysis.
In all the experiments described here, intracellular GzmB
staining of cell surface stained samples were conducted using
freshly isolated RBC-depleted splenocytes that were not stimulated
with peptides. For IFN-c and TNF-a ICS, 16106 cells in 200 ml of
Roswell Park Memorial Institute culture medium (Invitrogen,
Australia) containing 10% FCS were seeded in 96 well U-bottom
plates in the presence or absence of 0.1 mg/ml of A5275–83 or
F226–34 peptides. Subsequently, peptide stimulated or unstimu-
lated cultures were left for 1 hour at 37uC + 5% CO2 prior to
addition of 16Brefeldin A (eBioscience, USA). The cultures were
then left for further 4 hours at 37uC+5% CO2 prior to conducting
cell surface staining as described before.
Cell surface stained samples were fixed and permeabilized using
commercial intracellular fixation and permeabilization buffers
according to the manufacturer’s protocol (eBioscience, USA).
Subsequently, permeabilized cells were incubated 30 minutes at
4uC in the presence of purified or fluorochrome conjugated
antibodies diluted in 16 permeabilization buffer (eBioscience,
USA). Intracellular stained samples were washed twice using
Figure 8. STAT6 is required for IL-4 mediated attrition of VV-specific CD8+ T cell responses. BALB/c STAT6 2/2 (n = 4) and BALB/c WT
control mice (n = 5) were infected with 56106 PFU of VV-HA, VV-HA-IL-4 or kept unimmunized for 7 days prior to sacrifice and analysis using ICS after
in vitro peptide stimulation. A and B, Representative dot plots showing IFN-c and TNF-a expression on gated CD8+ splenocytes from infected BALB/c
WT (A) or BALB/c STAT6 2/2 (B) mice following in vitro stimulation of splenocytes with the indicated peptides. C, The mean (n = 4–5) number of
cytokine producing KdA5275–83 or K
dF226–34 specific CD8
+ splenocytes and the mean (n = 4–5) proportion of CD8+ splenocytes that produced TNF-a in
addition to IFN-c from BALB/c WT (top row of plots) or BALB/c STAT6 2/2 (bottom row of plots) mice infected with the indicated virus. The data are
representative of two independent experiments and the error bars depict the SEM. One-way ANOVA (Tukey’s Multiple Comparison) was used to
determine statistical significance of the data relative to VV-HA infected mice (* - p,0.05; ** - p,0.01; *** - p,0.001).
doi:10.1371/journal.pone.0055788.g008
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phosphate buffer saline containing 1% FCS, fixed in 0.5%
paraformaldehyde prior to analysis. All cell surface and intracel-
lular stained samples were analyzed using FACS Calibur (BD
Biosciences, USA) or BD LSR II (BD Biosciences, USA) machine.
Flow cytometry plots of the analyzed data were constructed using
the FlowJo Tree Star software (version 8.7.1).
Statistical analysis
Net fold reduction of cell surface IL-4Ra expression was calculated
using mean fluorescent intensity (MFI) obtained from flow cytometry
on gated CD8+ splenocytes from unimmunized or VV-WR infected
mice as follows: ((MFI (IL-4Ra)unimmunized2MFI (IL-4Ra)VV-WR)/
MFI (IL-4Ra)unimmunized). All the data presented in this study have
been reproduced in at least two independent experiments. The data
plotted in all the graphs shown represent the mean and the error bars
depict the standard error of the mean (SEM). Statistical significance
of the data and the p values were calculated using the Graph InStat
software (version 3.10). In all statistical significance analysis, a
student’s unpaired t-test or one-way ANOVA (Tukey’s Multiple
Comparison post-hoc test) was used. The p values are denoted as
follows: * - p,0.05, ** - p,0.01, and *** - p,0.001.
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